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To determine the prevalence of human immunodeficiency virus type 2 (HIV-2) subtypes circulating in France and to identify
possible relationships between these subtypes and pathogenesis, we studied 33 HIV-2-infected patients living in France.
HIV-2 DNA was directly amplified from peripheral blood mononuclear cells by nested PCR with specific HIV-2 env primers,
and the env gene was sequenced. The serological consequences of antigenic variability were studied by using a panel of
peptides and by Western blotting. Phylogenetic analysis classified the 33 HIV-2 strains as subtype A (n 5 23) or B (n 5 10).
There were no significant clinical or epidemiological differences between patients infected with either of these two subtypes.
There was some evidence for geographical clustering. Subtype A strains from patients originating from the Cape Verde
Islands and Guinea Bissau clustered together. The majority of patients infected with subtype B strains originated from the
Ivory Coast or Mali. Strains from patients originating in Mali also clustered in subtype A but distinctly from the Cape Verde
or Guinea Bissau strains. The subtype B strains showed greater diversity and included some highly divergent strains relative
to those previously characterized. The V3 loop of HIV-2 subtypes A and B was found to be quite conserved in comparison
with HIV-1. A strong HIV-2 subtype B serological cross-reactivity was found on HIV-1 env antigen by Western blot mostly in
the gp41 transmembrane glycoprotein. This could partly explain the double HIV-1 and HIV-2 reactive profiles found in
countries where HIV-2 subtype B is prevalent. © 2001 Academic Press
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tINTRODUCTION
Human immunodeficiency virus type 2 (HIV-2) is en-
demic in West Africa. The majority of cases diagnosed
outside this region have been detected in France and
Portugal, whereas only sporadic cases of HIV-2 infection
have been reported in other European countries, North
America, and Asia, generally reflecting epidemiological
links with individuals of West African origin (Kanki and
De Cock, 1994). HIV-1 and HIV-2 differ in their natural
history and in vivo pathogenicity (De Cock et al., 1993).
eterosexual and vertical transmission rates are lower
ith HIV-2 than with HIV-1 (Kanki et al., 1994; Matheron et
al., 1990). The clinical course of HIV-2 infection is longer
than that of HIV-1, leading to lesser morbidity and longer
patient survival (Ancelle et al., 1987; Matheron et al.,
1997). Compared with HIV-1, HIV-2 shows decreased cell
killing, syncytium formation, and replication rates (Castro
et al., 1990); it also interacts differently with CD4 (Reevers
et al., 1997; Sol et al., 1997). These features and the lower
eplication capacity are in keeping with the reduced
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19athogenicity of HIV-2 relative to HIV-1 (Simon et al.,
993).
In comparison to HIV-1, fewer HIV-2 strains have been
enetically characterized. However, the results of the
tudies have shown that HIV-2, similar to HIV-1, displays
arked genetic diversity, and at least seven subtypes
ave been identified (Chen et al., 1997; Gao et al., 1994;
harp et al., 1994). Differences in the biology of HIV-2
trains belonging to different subtypes have been re-
orted (Gao et al., 1994). The genomic organization and
hylogenetic similarity between HIV-2 and simian immu-
odeficiency virus (SIV)sm led to the proposal that each
IV-2 subtype is the result of a zoonosis originating from
SIVsm strain naturally infecting sooty mangabeys (Cer-
ocebus torquatus atys) in West Africa (Chen et al., 1997;
ao et al., 1994).
Altogether, these data support the need for extensive
lobal studies of HIV-2, with a view to monitoring prev-
lent genotypes for the purpose of epidemiological track-
ng and to obtain insights into the pathogenesis of HIV
nfection. Three years ago, the French National Agency
or AIDS Research (ANRS) commissioned a study based
n the clinical and virological follow-up of a cohort of
IV-2-infected patients living in France. So far, 124 pa-
ients have been enrolled, and the mean follow-up time is
6 months (range 0–93 months). Here we report the
0042-6822/01 $35.00
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20 DAMOND ET AL.genetic characteristics of sequences from 33 HIV-2 iso-
lates, the relative prevalence of different subtypes infect-
ing these patients, and investigations into correlations
between the viral subtype and pathogenesis. We also
investigated the serological repercussions of HIV-2 ge-
netic diversity by means of Western blotting and peptide-
based immunoassay.
RESULTS
Prevalence of HIV-2 subtypes in French patients
Sequencing and phylogenetic analysis indicate that
patients have been infected by HIV-2 subtype A (n 5 23)
and HIV-2 subtype B (n 5 10) (Table 1). Discounting the
infant’s strain, there were no statistically significant dif-
ferences between patients infected by these two HIV-2
T
Demographic, Immunological, and Virolo
No. Patient
Age
(yr) Sex Origin Treatm
1 96310 33 F Senegal NT
2 96150 30 F Cape Verde NT
3 97223 34 F Ivory Coast NT
4 96151 1 F Mali AZT/D
5 96201 29 M Poland NT
6 96330 39 M Morocco NT
7 96329 35 M Guinea Bissau NT
8 96152 47 M Senegal NT
9 96308 64 F Cape Verde NT
10 96199 37 F Cape Verde NT
11 96327 64 F Cape Verde AZT/3
12 96323 25 F Ivory Coast NT
13 96206 39 F Senegal NT
14 96324 31 M Guinea Bissau DD
15 96328 57 F France AZT
16 96226 41 M France AZT
17 96202 42 M Burkina Faso AZT/3
18 96205 29 F Ghana AZT
19 96325 43 M France AZT
20 96203 41 M Cape Verde AZT/3
21 96326 46 F Mali DD
22 9649 41 M Mali AZT/3
23 96207 46 M Mali AZT
24 97378 40 F Ivory Coast NT
25 97244 33 F Ivory Coast NT
26 97227 58 M Congo NT
27 96200 27 F Ivory Coast NT
28 96309 45 M Mali AZT
29 96339 56 F France NT
30 96307 39 M Mali AZT/D
31 97245 63 M France AZT/3TC
32 96306 47 M Senegal AZT
33 9644 37 M Ivory Coast AZT
Note. F, female; M, male; NT, not treated; and ND, not done.subtypes in terms of age, sex, presence or absence of fclinical signs, CD41 cell counts, or positive peripheral
blood mononuclear cell (PBMC) isolation (P . 0.05).
The correlation between viral isolation and CD41 cell
counts (Simon et al., 1993) was found (P , 0.01) and
as independent of the subtype.
CR amplification
Complete amplification of the envelope region corre-
ponding to the EB0 or EB2/ENVB or ENVG primer pairs
as successful in only 27 patients, of whom 19 were
nfected by subtype A strains. Conversely, the env seg-
ent encompassing the V3 region and the end of the
p36 transmembrane region was amplified in every
ase. Only the V2 region of the HIV-2 strains, previously
eported to be the most variable (Korber et al., 1995;
yers et al., 1996), was associated with amplification
haracteristics of the Study Participants
Disease
status
CD4
count
Cell
viremia
Plasma
viremia
Sequence
subtype
A 832 1 2 EB0/ENVGA
A 700 1 2 EB4/ENVBA
A 644 2 2 EB2/ENVGA
A 614 2 ND EB0/ENVBA
A 430 1 ND EB0/ENVGA
A 391 1 2 EB0/ENVGA
A 375 1 2 EB0/ENVBA
A 373 1 2 EB2/ENVGA
A 339 1 2 EB2/ENVGA
A 282 1 2 EB0/ENVGA
A 249 1 2 EB2/ENVGA
A 240 1 2 EB0/ENVBA
A 210 1 2 EB0/ENVGA
A 199 1 2 EB2/ENVGA
A 189 1 2 EB2/ENVGA
A 181 2 2 EB0/ENVBA
A 37 1 2 EB0/ENVGA
A 34 1 2 EB9/ENVGA
C 31 1 2 EB2/ENVGA
B 26 1 2 EB0/ENVDA
C 25 1 1 EB2/ENVGA
C 24 1 2 EB4/ENVBA
C 13 1 1 EB0/ENVGA
A 800 2 ND EB2/ENVBB
A 799 2 2 EB2/ENVBB
A 448 2 2 EB0/ENVFB
A 347 1 2 EB2/ENVGB
C 283 1 2 EB2/ENVGB
A 258 1 2 EB0/ENVBB
A 153 1 2 EB0/ENVGB
A 139 2 2 EB2/ENVBB
C 120 1 2 EB2/ENVGB
A 97 1 1 EB4/ENVBBABLE 1
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21HIV-2 DIVERSITY IN FRANCENucleotide and amino acid analyses confirm the low
HIV-2 env variability
The HIV-2 env sequences obtained by direct PCR
amplification showed a virtual lack of ambiguous posi-
tions necessitating manual correction, in marked con-
trast with HIV-1 (Myers et al., 1996). No major deletions
or insertions were observed in the V3 or gp36 regions,
which were highly conserved. Glycosylation sites were
present in positions similar to those previously de-
scribed (Boeri et al., 1992). Viral variability seemed to be
limited, ranging from 3.9% to 14% for subtype A and from
2.9% to 14% for subtype B. The V3 region appeared to be
highly conserved, in contrast with HIV-1 (Fig. 1). Viral
sequences corresponding to the V3 loop were similar in
strains belonging to subtypes A and B. The only consis-
tent difference was the replacement of a leucine before
the tip of the loop in almost all subtype A strains by either
a valine or an isoleucine in subtype B strains. All of the
V3 loops of subtype A and B strains bore a strong
FIG. 1. Comparison of the newly derived HIV-2 amino apositive charge (15 and 18, respectively). Negatively lharged amino acids were rare, and only two strains,
solated from symptomatic patients, harbored a glutamic
cid in the descending region of the V3 loop. The amino
cid sequence of the immunodominant region of the
p36 transmembrane glycoprotein of subtype A strains
as remarkably conserved (Fig. 2), with no mutation
eing encountered in the small loop. Some signatures in
equence were observed on almost all of the HIV-2
ubtype B strains investigated. The methionine before
he immunodominant region of the gp36 in all but two
96326, 96203) of the subtype A strains was replaced by
leucine in all but one (97244) subtype B strains. This
utation was also observed in HIV-1, SIVsyk, and
IVmnd; the sabaeus strain was the only SIV that har-
ored a methionine in this position (Mu¨ller et al., 1993).
nother specific subtype B mutation was the replace-
ent of the glutamine immediately preceding the loop by
leucine, as in HIV-1 and SIVmnd strains. Finally, two
ubtype B strains bore a major substitution within the
uences from the V3 region with the HIV-2 strain ROD.oop, the alanine described in all HIV-2 strains so far
from th
e also
22 DAMOND ET AL.characterized being replaced by a serine. This little loop
is an important antigenic domain used in all of the
screening tests for anti-HIV-1 or anti-HIV-2 antibodies
detection. The two sera corresponding to these strains
with a serine substitution were weakly reactive in differ-
ent screening tests, with one sample (97378) giving re-
peatedly negative results in a HIV-1/HIV-2 screening as-
say.
Functional sites of the HIV-2 envelope
The V2 region appeared highly variable, whereas the
FIG. 2. Comparison of the newly derived HIV-2 amino acid sequences
for HIV-1 group M, SIVsmH4, SIVagmSAB1, SIVsyk, and SIVmndGB1 arV3 loop was highly conserved. The high mutation ratepointed to strong selective pressure on the V2 region, as
in the V3 loop of HIV-1 strains. The C4 region, which
contains the CD4 binding site, was highly conserved. We
observed no deletions in the regions corresponding to
the gp36 transmembrane protein. The ascending branch
of the V4 loop seemed to be highly conserved, whereas
the descending region was more variable.
Phylogenetic analyses
After confirmation as a subtype A strain, the sequence
96207 was excluded from the phylogenetic analysis be-
e immunodominant region with the HIV-2 strain ROD. The same region
shown with reference to HIV-2/ROD.cause of its short length (540 bp). After exclusion of
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23HIV-2 DIVERSITY IN FRANCEgap-containing sites, 1320 sites were left in the align-
ment. All of the newly derived sequences clustered in
either HIV-2 subtype A or B (Fig. 3), as assessed by high
bootstrap values. The use of different phylogenetic meth-
ods did not alter these significant clusterings. Recombi-
nation analysis (not shown) showed that none of these
newly derived strains were HIV-2 intersubtype recombi-
nants. However, four of the newly derived subtype A
strains (96152, 96201, 96323, and 97223) clustered incon-
sistently with HIV-2 subclusters A1 and A2 (Breuer et al.,
1995). Also, the previously characterized strain CAM4
(Breuer et al., 1995) clustered either with subcluster A2 or
s a third HIV-2 subtype A lineage. These five strains,
FIG. 3. Phylogenetic relationships of the newly characterized viruses
(in red) to representatives of the HIV-2 subtypes A and B (indicated on
the right), SIVsmH4, and SIVmac251 from the Los Alamos HIV se-
quence database (http://hiv-web.lanl.gov). The tree was constructed
using the neighbor-joining method from env nucleotide sequences
1320 sites were left after gap-containing sites were removed from the
lignment). Horizontal branches lengths are to scale (the scale bar
epresents 0.02 substitution per site); vertical separation is for clarity
nly. Values at the nodes indicate the percent bootstraps of 1000
eplicates in which the cluster to the right was supported (values of 75%
nd higher are shown). The letters to the right of the sequence names
re the country codes for the origin of the patients (see Fig. 4 legend
or full country name). Country codes in brackets represent probable
lace of infection if different and known.nd the known hybrid GH1 (Takehisa et al., 1997), wereexcluded from the alignment and the phylogenetic trees
reconstructured. After exclusion of these putative HIV-2
intrasubtype hybrids, subtype A subclusters A1 and A2
were clearly identified in the phylogeny, supported by
significant bootstrap values (Fig. 4).
Within subtype B, two strains that clustered together
significantly were quite distinct to previously character-
ized HIV-2 subtype B strains. These two strains (97378
and 96339) were isolated from an Ivory Coast patient and
a French woman infected via blood transfusion in the
Ivory Coast in 1982.
FIG. 4. Phylogenetic relationships of the newly characterized viruses
derived after exclusion of putative recombinants (see text for details)
from the same gap-stripped multiple alignment used in Fig. 3. Se-
quence names and country codes are shown in color for Cape Verde
(CV, light blue), Ivory Coast (IVC, red), Guinea Bissau (GNB, green), Mali
(MLI, dark blue), and Senegal (SEN, purple). The other country codes
are for Burkina Faso (BFA), Congo (COG), Gambia (GMB), Germany
(DEU), Ghana (GHA), France (FRA), Poland (POL), and Portugal (PRT).
Horizontal branches lengths are to scale (the scale bar represents 0.02
substitution per site); vertical separation is for clarity only. Values at the
nodes indicate the percent bootstraps of 1000 replicates in which the
cluster to the right was supported (values of 75% and higher are
shown).
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24 DAMOND ET AL.Reactivity of HIV-2 sera with V3 peptides
There was no reactivity between HIV-2 sera and the V3
peptides of HIV-1 M or N, SIVcpz, or SIVmnd. Only sera
from the two patients with dual HIV-1/2 infection reacted
with the HIV-1 group M V3 peptide. Reactivity with the
peptide V3 SIVagm was limited, with HIV-2 subtype B
sera being significantly more reactive than subtype A
sera: only 4 of the 21 subtype A sera reacted with SIVagm
V3 peptide, 1 of which was at the cutoff value, compared
with 7 of the 10 subtype B sera (P 5 0.01).
Reactivity of HIV-2 sera with peptides mapping to the
immunodominant region
Only the sera from the dually infected patients reacted
with the HIV-1/SIVcpz gp41 epitopes. None of the sub-
type A sera reacted with gp41 peptides from the immu-
nodominant region of HIV-1 M, N, or SIVcpz (Table 2). Six
of the 21 subtype A sera cross-reacted weakly with
SIVmnd peptide, with the OD values always being less
than 0.4. All of the HIV-2 subtype A sera reacted strongly
with SIVagm and SIVsm gp36 peptides. Subtype B sera
gave different patterns of reactivity. The sera of six pa-
tients reacted with one or more HIV-1/SIVcpz peptides.
Two of these patients (96339 and 97378) were infected
by phylogenetically “distant” subtype B strains, and se-
rum from one (97378) reacted strongly with SIVcpz pep-
tides. All of the sera except one reacted strongly with
SIVagm and SIVsm peptides; the serum from patient
97378 was negative with SIVagm and weakly reactive
with SIVsm peptide. The reactivity of subtype B sera with
SIVmnd peptide must be underlined, with 7 of the 10 sera
being positive (Table 2).
Reactivity of HIV-2 sera with HIV-1 and HIV-2 Western
blot antigens
Figure 5 shows the reactivity of sera from individuals
infected with subtypes A and B in commercial Western
blots prepared from the HIV-1 subtype B strain LAI and
the HIV-2 subtype A strain ROD. The cross-reactivity
pattern of HIV-2 subtype A sera in HIV-1 WB was as
classically described (i.e., strong reactivity against inter-
nal proteins and no reactivity with HIV-1 glycoproteins).
TABLE 2
Reactivity of HIV-2 Sera with Peptides Mapping to the
Immunodominant Region
No. of sera
tested
Reactive sera against gp41 HIV-1 or SIV peptides
M and/or N SIVmnd SIVagm SIVsm
(n 5 21) a 0 6 21 21
(n 5 10) 6 7 9 10a Samples from two dual-infected patients excluded.Only three subtype A sera reacted, faintly, with gp160.
However, the subtype B sera cross-reactivity pattern in
HIV-1 WB was different from that classically described:
all subtype B sera reacted with gp160, and six cross-
reacted strongly with gp120. Such reactivity may be mis-
interpreted as indicating an HIV-1-seropositive result.
Although these patients reacted in both HIV-1 and HIV-2
WB, dual infection was formally excluded by molecular
biology (all H-pol HIV-1 amplifications being negative)
and by their negativity with V3 HIV-1 peptides. The clin-
ical, immunological, and virological data on patients with
subtypes A and B were comparable (Table 1), thus ex-
cluding the involvement of factors other than the infect-
ing subtype in the cross-reactivity patterns.
DISCUSSION
HIV-2 subtypes A and B display similar in vivo
pathogenicity
Based on the frequency of virus isolation and the
absence of symptoms in patients infected by HIV-2 non-
subtype A, Gao et al. (1994) proposed that HIV-2 sub-
types might differ in their in vivo pathogenicity. We have
previously shown that the HIV-2 cellular loads are related
to the replication potential of HIV-2 strains (Simon et al.,
1993). HIV-2 virus load was determined in both plasma
and infected PBMCs by limiting dilution analysis and
correlated only with CD4 counts (Simon et al., 1993;
Damond et al., 1998). Our present results show no dif-
ference between the isolation rates (from both PBMCs
and plasma) of subtypes A and B and confirm that viral
isolation correlates with the clinical and immunological
stage of infection.
HIV-2 replicates more slowly and is thus less variable
than HIV-1
Analysis of the nucleotide sequences of the env gene
of our 33 HIV-2 strains of different geographical origin
confirmed lower variability compared with HIV-1, re-
flected by strong inter-isolate homology in the env gene,
the most variable region of HIV (Fig. 1).
The V1–V2 regions of our HIV-2 strains, particularly
subtype B strains, were difficult to amplify with our prim-
ers. Observations in the SIVmac model (McKnight et al.,
1996) might explain V2 region variability as a response to
humoral and/or cellular immune selection pressures.
The V2 region contains an important site, between amino
acids 140–181, that is recognized by monoclonal antibod-
ies that neutralize the infectivity of HIV-2 and SIVsm
(McKnight et al., 1996). The conserved HIV-2 V3 loop
contrasts with the high variability of this region in HIV-1
strains. Several studies have shown that the V3 loop is
highly conserved in HIV-2 strains but suggested that
clinically significant mutations might occur within this
domain (Franchini et al., 1990). In this cross-sectional
25HIV-2 DIVERSITY IN FRANCEFIG. 5. The reactivity of subtypes A and B with commercial Western blots prepared from the HIV-1 subtype B strain LAI and the HIV-2 subtype A
strain ROD.
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26 DAMOND ET AL.study, we observed no significant differences in the num-
ber of mutations according to the clinical stage, with
strains from seven symptomatic patients having highly
conserved V3 loop sequences (Fig. 1). In the absence of
prospective analyses, we cannot draw conclusions re-
garding the variability of the V3 loop in HIV-2 infection
(Boeri et al., 1992). The ascending branch of the V4 loop
seemed to be highly conserved, whereas mutations
were found in the descending branch. Conversely, the C4
region, which contains the CD4 binding site, was highly
conserved. We failed to detect truncation of the trans-
membrane glycoprotein gp36 in amplification products
obtained from fresh lymphocytes.
Phylogenetic clustering correlates with strain
geographical origin
A correlation was found between some of the patients’
country of origin (probable place of infection) and the
infecting HIV-2 subtype. Most patients infected by sub-
type B strains originated from the Ivory Coast and Mali
(the two French patients with subtype B infection had
been infected in the Ivory Coast). Strains from patients
originating from Mali also clustered in subtype A1 but
were distinct from the Cape Verde or Guinea Bissau
strains. All of the patients from the Cape Verde Islands
and Guinea-Bissau were infected by subtype A2 strains.
The other country of origin, Senegal, from which multiple
patients originated showed no phylogenetic clustering.
These phylogenetic distinctions within subtype A sup-
port the phenotypic analyses of the V3 loop (Korber et al.,
1995), which revealed two distinct phenotypic patterns,
one of which was represented by strains from Guinea-
Bissau. It has been proposed that these strains formed
an ancient cluster of HIV-2 subtype A strains (Breuer et
al., 1995). However, seroepidemiological data on the
prevalence of HIV-2 suggest that this virus has circulated
for several decades in Guinea-Bissau (Pepin et al., 1991;
Wilkins et al., 1993). The circulation of subtype A and its
founder effect in this region are supported by the close
historical and linguistic relations between Cape Verde
and Guinea-Bissau. Chronological and geographical fea-
tures of subtype A strain evolution could explain the
diversity of this subtype. This might be confirmed by
analysis of circulating strains in other Portuguese-speak-
ing countries. Unfortunately, no HIV-2 strains from Angola
or Mozambique have yet been sequenced.
HIV-2 subtype B has been present in the Ivory Coast
since 1982
Patient 96339, infected by HIV-2 subtype B, was in-
fected via transfusion during a pregnancy 16 years ear-
lier in the Ivory Coast. Her child was vertically infected by
HIV-2 subtype B. The sequence homologies between the
strains isolated from the mother and child showed that
transmission took place during the pregnancy. Thisproves that HIV-2 subtype B has been circulating in West
Africa since at least 1982. Although we found subtype B
strains in patients originating from other West African
countries, the majority were from the Ivory Coast or Mali.
Genetic diversity of HIV-2 is similar to that of HIV-1
The low slopes of HIV-2 nonsynonymous/synonymous
substitution ratios relative to HIV imply that HIV-2 should
show less diversity than HIV-1 (Korber et al., 1995). How-
ever, intersubtype genetic distances for HIV-2 subtypes A
and B are similar to those calculated for HIV-1 group M
subtypes (Chen et al., 1997; Gao et al., 1994). Moreover,
IV-2 subtypes D and F are even more variable, with the
enetic distances from other HIV-2 subtypes being more
han 30% (Chen et al., 1997). This peculiar subtype vari-
ability of HIV-2 is explained by the HIV-1 subtypes rep-
resenting diversification of virus in the human popula-
tion, whereas the HIV-2 subtypes each represent an
independent zoonosis event (i.e., HIV-2 subtypes are
comparable to the HIV-1 groups M, N, and O). In addition,
even if strains replicate less, the accumulation of muta-
tions will generate marked diversity over the years, as
already observed with SIVagm strains (Jin et al., 1994;
u¨ller et al., 1993). The strong divergence of SIVagm
solated from different subspecies of Chlorocebus ae-
hiops, coupled with the low replication potential of these
trains, suggests that SIVagm has been circulating
mong these monkeys for many years (Jin et al., 1994).
erological consequences of HIV-2 variability confirm
he genetic diversity
Some subtype B HIV-2 strains generated serological
ross-reactivity with HIV-1 glycoproteins in this study.
IV-2 subtype B is endemic in the Ivory Coast, the coun-
ry where the bulk of double WB reactivity has been
eported (De Cock et al., 1993; George et al., 1992;
eeters et al., 1992; Rayfield et al., 1988). Analysis of
subtype B gp36 sequences showed the importance of
the leucines preceding the little loop of the immunodom-
inant region. These leucines are present in the same
position in all simian strains and in similar positions in
HIV-1 strains. This potential explanation for dual sero-
logic reactivity does not exclude the existence of dual
infections but stresses the importance of very strict cri-
teria for coherent and consensual definition of dual re-
activity. HIV-2 subtype B could be more frequent than
believed and misidentified as HIV-1 because of the high
cross-reactivity.
Synthetic peptides might be used in a confirmatory
test for dual infection
The two dually infected patients reacted with peptides
of both HIV-1 and HIV-2/SIV. We also tested five other
patients diagnosed as being dually infected in our labo-
ratory, and all reacted with both peptides (data not
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27HIV-2 DIVERSITY IN FRANCEshown). A combination of our amplification strategy,
which has 95% sensitivity (Damond et al., 1998), and
synthetic peptides mapping to the V3 region EIA might
be of value in epidemiological studies on the signifi-
cance of dual reactivity and dual infection.
Consequences of HIV-2 diversity for blood screening
strategies
We have previously demonstrated that viral diversity
can have an important influence on the performance of
HIV screening tests. Some antibody screening tests fail
to reliably detect infection by HIV-1 group O viruses
(Simon et al., 1994). The present study shows that the
same problem may be encountered with HIV-2. Sera from
a patient infected by HIV-2 subtype B (97378) gave a
negative result when tested in a third-generation screen-
ing assay (Genscreen; Sanofi Diagnostics Pasteur, Paris,
France), leading the manufacturer to modify the peptide-
antigen used in this assay to improve the HIV-2 detect-
ability. Although we had insufficient serum to test other
screening kits, this shows that the design of screening
assays should be carefully evaluated and regularly im-
proved to cover the diversity of HIV.
Conclusions
We observed significant diversity among HIV-2 strains
isolated in France. One third of the patients were in-
fected by HIV-2 subtype B. This viral diversity may have
public health implications, especially regarding screen-
ing for HIV-2 subtype B infection. The frequent cross-
reactivity with antigens of the gp36 immunodominant
domain may partly explain the high frequency of HIV-1/
HIV-2 dual reactivity observed in places like the Ivory
Coast, where HIV-2 subtype B is endemic. Finally, the
lack of clinical and epidemiological differences between
patients infected by subtypes A and B shows that the in
vivo pathogenicities of the two subtypes are very similar.
MATERIALS AND METHODS
Subjects
Table 1 shows the sociodemographic, immunologi-
cal, and virological characteristics of the study popu-
lation. Twenty-eight adults were enrolled who were
attending Bichat Hospital, were included in the French
HIV-2 cohort, and were diagnosed between June 1994
and March 1997. An additional five patients not in the
French cohort were enrolled because of their clinical
and biological significance: a child who was vertically
infected by HIV-2 (96151), two adults with dual HIV-1/
HIV-2 infection (96152 and 96205), a recent HIV-2
seroconvertor (96201), and a patient (97378) infected
by HIV-2 but whose serum was nonreactive in a third-
generation ELISA test (Genscreen HIV-1/HIV-2; Sanofi
Diagnostics Pasteur). All of the patients were living in cthe Paris region, except for one (97378), who was
living in the north of France. The patients (17 males
and 16 females) were born in various countries in
West Africa (Burkina Faso, 1; Cape Verde Islands, 5;
Ghana, 1; Guinea Bissau, 2; Ivory Coast, 6; Mali, 6;
Senegal, 4), Central Africa (Congo, 1), North Africa
(Morocco, 1), or Europe (France, 5; Poland, 1). The
European and North African patients reported hetero-
sexual contacts in West Africa or with West African
partners; two of the French patients received blood
transfusions in the Ivory Coast. According to the Cen-
ters for Disease Control and Prevention (CDC) classi-
fication (CDC, 1993), 26 patients were at stage A, 1
was at stage B, and 6 were at stage C. CD41 cell
ounts were above 500 3 106/L in 6 patients (female),
00–500 in 13 patients (6 males and 7 females), and
elow 200 in 14 patients (11 males and 3 females). Ten
atients were on antiretroviral monotherapy (AZT, 8;
dC, 2), six were on two-drug regimens (AZT/3TC, 4;
ZT/ddI, 2), and one was on a three-drug combination
AZT/3TC/IDV).
irological diagnosis
HIV-2 infection was serologically confirmed by West-
rn blot (New Lav Blot 2; Sanofi-Diagnostics Pasteur).
irological confirmation or exclusion of HIV-1/HIV-2 coin-
ection was systematically performed by amplification of
he HIV-1 pol gene in the integrase region (Fransen et al.,
994). The two HIV-1 strains recovered from fresh PB-
Cs from dually HIV-1- and HIV-2-infected patients were
enotyped by means of HMA and shown to belong to
IV-1 subtype A.
All sera were also tested by HIV-1 Western blot (New
av Blot 1; Sanofi-Diagnostics Pasteur) to identify sero-
ogical cross-reactions of the different HIV-2 subtypes in
IV-1 tests.
ultures
Cells and plasma were cultured from each sample,
nd cellular and plasma viremia were measured as pre-
iously described (Simon et al., 1993).
CR
DNA from fresh PBMCs was extracted with phenol–
hloroform, precipitated with ethanol, and quantified
pectrophotometrically. HIV-2 DNA was amplified by
ested PCR with first-round long (XL) PCR. The Gene
mp XL PCR method was used according to the manu-
acturer’s instructions (Perkin–Elmer Cetus, Applied Bio-
ystems, Alameda, CA). We designed the following
rimer pairs for use in the first amplification step: PFD
59-)/LTR9574 (39-) and LTR1 (59-)/LTR2 (39-) (Damond et
l., 1998). One microgram of genomic DNA was sub-
ected to first-round amplification. The PCR conditions
onsisted of initial denaturation at 94°C for 1 min, fol-
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28 DAMOND ET AL.lowed by 16 cycles of denaturation at 94°C for 15 s,
annealing at 55°C for 1 min, and extension at 68°C for 5
min. The subsequent 24 cycles were carried out in the
same conditions, with incremental lengthening of the
extension time (15 s cycle) and a last extension step at
68°C for 10 min. HLADQa was routinely amplified as a
PCR efficiency control. The following primer pairs were
used for nested PCR: EB0/EB6, EB2/EB5, EB7/ENVE,
ENVA/ENVB, and ENVF/ENVG, corresponding to the V2
and V3 hypervariable regions, the V3–gp36 junction, the
gp36 region, and the terminal domain of the HIV-2 env
gene, respectively (Damond et al., 1998). The nested PCR
procedure consisted of amplifying 5 ml of the first XL PCR
product in a final volume of 100 ml with 10 ml of PCR
buffer, 200 mM concentration of each dNTP, 30 pmol of
inner primers, and 2 U of Taq polymerase. The PCR
conditions were as follows: 40 amplification cycles, with
denaturation at 94°C for 5 min followed by 38 cycles (30
s at 94°C, 30 s at 55°C, and 30 s at 72°C) and a last
extension step at 72°C for 7 min. PBMC DNA from
healthy blood donors was introduced in each reaction.
Nested PCR products were analyzed on 1.4% agarose gel
stained with ethidium bromide.
DNA sequence analysis
The PCR products were purified using the Qiagen gel
extraction kit (Chatsworth, CA). Sense and antisense
DNA templates were then used as matrices for the cor-
responding primers in the Dye Terminator kit (Applied
Biosystems, Foster City, CA). Sequencing reactions were
run on an automated DNA sequencer (Applied Biosys-
tems 373A).
Phylogenetic analysis
The phylogenetic relationships of the newly derived
HIV-2 strains were estimated from sequence compari-
sons with previously reported representatives of the HIV-
2/SIVsm primate lentivirus lineage. A multiple env align-
ment was obtained from the Los Alamos HIV sequence
database (http://hiv-web.lanl.gov), and the newly derived
HIV-2 env sequences were included into this alignment
using the CLUSTAL W profile alignment option (Thomp-
son et al., 1994). Where necessary, the alignment was
adjusted manually with the SeaView alignment editor
(Galtier et al., 1996). All partial reference sequences were
removed from the alignment. All gap-containing sites
were excluded from the analysis. Phylogenetic trees
were constructed by the neighbor-joining method using
the Kimura two-parameter and HKY corrections (Hase-
gawa et al., 1985; Kimura, 1980). Maximum parsimony
analyses were performed using DNAPARS, with 10 ran-
domizations of sequence input order (Feselstein, 1993).
Maximum likelihood analyses were performed using
FASTDNAML (Olsen et al., 1994). The reliability of the
neighbor-joining topologies were estimated by perform-ing 1000 bootstrap replicates. These methods were im-
plemented with Phylo_Win (Galtier et al., 1996).
Putative recombinants were identified by constructing
phylogenetic trees from fragments of the same gap-
stripped multiple alignment using a window length of 400
bp moved in 50-bp increments. These trees were derived
by the neighbor-joining method using Kimura’s two-pa-
rameter correction, implemented with CLUSTAL W. Nine-
teen trees were inspected for evidence of inconsistent
phylogenetic clustering. Putative hybrid sequences were
analyzed by diversity plotting at http://igs-server.cnrs-
mrs.fr/anrs/phylogenetics, using a window length of 400
bp and an increment of 10 bp.
Nucleotide sequence accession numbers
All sequences have been submitted to GenBank with
accession numbers AF170029 to AF170061.
Synthetic-peptide ELISA
Peptides corresponding to the gp41 immunodominant
domain and peptides corresponding to the V3 loop from
different strains infecting human and nonhuman pri-
mates were synthesized to 80% purity (Ne´oSystems,
Strasbourg, France). HIV-1 group M (subtype A consen-
sus), HIV-1 group N (YBF30), SIVcpzGAB1, SIVmndGB1,
SIVagmSAB1, and SIVsmH4 gp41 and V3 loop peptides
were synthesized (Table 3). Polyvinyl microtiter plates
(Falcon) were coated with 100 ml/well of 2 mg/ml diluted
n 0.05 M bicarbonate buffer, pH 9.6, by incubation for
0 h at 37°C. The wells were then washed twice with
BS containing 0.5% Tween 20 (PBS-TW), and unoccu-
ied sites were saturated with PBS containing 2% new-
orn calf serum (NBCS) by incubation for 45 min at 37°C,
ollowed by washing in PBS-TW. Every serum sample
as tested at 1:100 dilution in 0.01 M sodium phosphate
uffer, pH 7.4, containing 0.75 M NaCl, 10% NBCS, and
.5% Tween 20 (PBS-TW-NBCS). The reactivity of each
ample was tested with all of the peptides. Diluted se-
um (100 ml) was added to the wells and incubated for 30
min at room temperature. The wells were then washed
four times with PBS-TW, and peroxidase-conjugated goat
F(ab9)2 anti-human immunoglobulin (Tago, Burlingame,
A; 100 ml of a 1:5000 dilution in PBS-TW-NBCS) was
added and incubated for 30 min at room temperature.
The wells were washed again four times with PBS-TW,
and the reaction was revealed by incubation with hydro-
gen peroxide-o-phenylenediamine (H2O2-OPD) for 15
in at room temperature. Color development was
topped with 2 N H2SO4, and absorbance (optical den-
sity) was read at 492 nm. We first validated our peptide
EIA with a panel of referenced sera. We selected 100
human and 80 simian sera (chimpanzees, African green
monkeys, and mandrills) that were HIV/SIV seronegative
by a whole virus lysate EIA (Organon Tecknika, Durham,
NC). All of these sera yielded an optical density of less
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29HIV-2 DIVERSITY IN FRANCEthan 0.05 with our synthetic peptide EIA. Thus a positive
cutoff at 0.15 was considered to be highly specific. We
then tested a large number of HIV-1-positive (n 5 100),
IV-2-positive (n 5 100), and SIV-positive (n 5 40) sera.
he SIV-positive panel corresponds to sera collected
rom 5 apes infected with SIVcpz, 20 African green mon-
eys (10 vervets and 10 sabeus), 10 mandrills, and 5
ooty mangabeys. All of these sera from HIV-infected
atients and SIV-infected primates reacted with their
omologous V3 and/or gp41 peptides.
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